The History and Development of HER2 Inhibitors
HER2 is highly expressed in a variety of malignant tumors and affects the prognosis of patients, making it a highly sensitive target for cancer therapy. Since the approval of the first HER2 inhibitor, trastuzumab, in 1998, HER2-targeted drugs have rapidly evolved. Currently, targeting HER2 drugs mai...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/16/10/1450 |
| _version_ | 1797572666452869120 |
|---|---|
| author | Xiaohui Xia Chen Gong Yinan Zhang Huihua Xiong |
| author_facet | Xiaohui Xia Chen Gong Yinan Zhang Huihua Xiong |
| author_sort | Xiaohui Xia |
| collection | DOAJ |
| description | HER2 is highly expressed in a variety of malignant tumors and affects the prognosis of patients, making it a highly sensitive target for cancer therapy. Since the approval of the first HER2 inhibitor, trastuzumab, in 1998, HER2-targeted drugs have rapidly evolved. Currently, targeting HER2 drugs mainly include monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs). This article reviews the development of HER2 inhibitors for various tumors over the past 20 years. |
| first_indexed | 2024-03-10T20:59:12Z |
| format | Article |
| id | doaj.art-f653f1a47f8f43fdb70e499db3e8ba98 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-10T20:59:12Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-f653f1a47f8f43fdb70e499db3e8ba982023-11-19T17:42:41ZengMDPI AGPharmaceuticals1424-82472023-10-011610145010.3390/ph16101450The History and Development of HER2 InhibitorsXiaohui Xia0Chen Gong1Yinan Zhang2Huihua Xiong3Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaSchool of Chemical Science and Engineering, Tongji University, Shanghai 200092, ChinaDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaHER2 is highly expressed in a variety of malignant tumors and affects the prognosis of patients, making it a highly sensitive target for cancer therapy. Since the approval of the first HER2 inhibitor, trastuzumab, in 1998, HER2-targeted drugs have rapidly evolved. Currently, targeting HER2 drugs mainly include monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs). This article reviews the development of HER2 inhibitors for various tumors over the past 20 years.https://www.mdpi.com/1424-8247/16/10/1450HER2 inhibitorscancerantibodiestyrosine kinase inhibitorsantibody-drug conjugates |
| spellingShingle | Xiaohui Xia Chen Gong Yinan Zhang Huihua Xiong The History and Development of HER2 Inhibitors Pharmaceuticals HER2 inhibitors cancer antibodies tyrosine kinase inhibitors antibody-drug conjugates |
| title | The History and Development of HER2 Inhibitors |
| title_full | The History and Development of HER2 Inhibitors |
| title_fullStr | The History and Development of HER2 Inhibitors |
| title_full_unstemmed | The History and Development of HER2 Inhibitors |
| title_short | The History and Development of HER2 Inhibitors |
| title_sort | history and development of her2 inhibitors |
| topic | HER2 inhibitors cancer antibodies tyrosine kinase inhibitors antibody-drug conjugates |
| url | https://www.mdpi.com/1424-8247/16/10/1450 |
| work_keys_str_mv | AT xiaohuixia thehistoryanddevelopmentofher2inhibitors AT chengong thehistoryanddevelopmentofher2inhibitors AT yinanzhang thehistoryanddevelopmentofher2inhibitors AT huihuaxiong thehistoryanddevelopmentofher2inhibitors AT xiaohuixia historyanddevelopmentofher2inhibitors AT chengong historyanddevelopmentofher2inhibitors AT yinanzhang historyanddevelopmentofher2inhibitors AT huihuaxiong historyanddevelopmentofher2inhibitors |